SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Akari Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Continued Progress Toward Clinical Development of Differentia

Initiated GLP toxicology studies of lead TROP2-targeted ADC AKTX-101 to enable planned Phase 1 trial

AKTX

Related stories